首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % HPLC. |
| 种属 | Human |
| 靶点 | CCL14 |
| Uniprot No | Q16627 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-93aa |
| 氨基酸序列 | TESSSRGPYHPSECCFTYTTYKIPRQRIMDYYETNSQCSKPGIVFITKRG HSVCTNPSDKWVQDYIKDMKEN |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL14重组蛋白的3篇参考文献示例(注：以下内容为模拟示例，实际文献需根据具体研究检索)：
1. **文献名称**：*Recombinant CCL14 regulates monocyte migration via CCR1 activation*
**作者**：Lee S, et al.
**摘要**：研究利用大肠杆菌系统表达重组CCL14蛋白，并验证其通过结合趋化因子受体CCR1诱导单核细胞迁移的能力，揭示了CCL14在炎症反应中的潜在作用机制。
2. **文献名称**：*Structural and functional characterization of human CCL14 and its isoforms*
**作者**：Zhang Y, et al.
**摘要**：通过哺乳动物细胞表达系统纯化CCL14及其剪接变体，分析其二级结构差异，发现不同异构体在调控中性粒细胞趋化活性中的功能特异性。
3. **文献名称**：*CCL14 suppresses tumor growth by enhancing anti-tumor T cell responses*
**作者**：Wang H, et al.
**摘要**：研究证明重组CCL14蛋白通过招募树突状细胞和激活CD8+ T细胞抑制小鼠模型中的黑色素瘤进展，提示其作为免疫治疗靶点的潜力。
如需真实文献，建议通过PubMed或Google Scholar以“CCL14 recombinant protein”或“CCL14 chemokine function”为关键词检索。
CCL14 (Chemokine (C-C motif) ligand 14), also known as HCC-1 or MCIF, is a small secreted protein belonging to the CC chemokine family. It is encoded by the *CCL14* gene in humans and plays a role in immune regulation by recruiting leukocytes to sites of inflammation or injury. Structurally, CCL14 contains conserved cysteine residues characteristic of CC chemokines, forming a monomeric structure that interacts with G protein-coupled receptors, primarily CCR1. CCR3. and CCR5.
The native form of CCL14 exists as an inactive precursor (pro-CCL14) that requires proteolytic processing by enzymes like MMP-1 or cathepsin D to generate bioactive isoforms, such as CCL14(9-74), which exhibit potent chemotactic activity. Recombinant CCL14 is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its functional properties without dependence on natural proteolytic activation.
Biologically, CCL14 is implicated in diverse processes, including inflammation, tissue repair, and cancer progression. It attracts monocytes, lymphocytes, and eosinophils, modulating immune responses in conditions like fibrosis, chronic kidney disease, and tumor microenvironments. In cancer, CCL14 may promote angiogenesis or immunosuppression, though its precise mechanisms remain debated.
Recombinant CCL14 proteins are widely used in research to dissect chemokine-receptor interactions, signaling pathways, and therapeutic potential. For instance, engineered CCL14 variants or receptor antagonists are explored for treating inflammatory disorders or metastatic cancers. Despite progress, key questions persist regarding its context-dependent roles, isoform-specific effects, and regulatory networks, underscoring the need for further mechanistic studies. Overall, recombinant CCL14 serves as a vital tool for unraveling chemokine biology and developing targeted immunotherapies.
×
